The dispute centred around Gilead's triple-drug regimen Biktarvy, which is based on emtricitabine, tenofovir alafenamide and integrase inhibitor bictegravir. ViiV claimed the latter compound ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing ... against strains that have developed resistance to earlier drugs in the class, like ...

Biktarvy is Gilead's biggest drug. Gilead stock popped 6.8% to close at 97.90. That put shares in a profit-taking zone after breaking out of a cup-with-handle base and 78.45 buy point on Aug.

The strong momentum in Biktarvy has enabled Gilead to increase its HIV sales target to 5% in 2024 from the earlier estimate of 4%. Gilead’s efforts to innovate its HIV portfolio are impressive.

These efforts are part of a long-term strategy to mitigate the impact of Biktarvy's loss of exclusivity (LoE) anticipated in 2033. Gilead's oncology franchise, led by Trodelvy and Cell therapy ...

These efforts are part of a long-term strategy to mitigate the impact of Biktarvy's loss of exclusivity (LoE) anticipated in 2033. Gilead's oncology franchise, led by Trodelvy and Cell therapy, is ...

Proposed Medicaid cuts may create risks for biopharma, impacting drugs like AbbVie’s Humira and Gilead’s Biktarvy. Get Wall Street's Hottest Chart Every Morning Medicaid funding, totaling ...